|
業務類別
|
Biotechnology |
|
業務概覽
|
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors. |
| 公司地址
| 500 Technology Square, Suite 700, Cambridge, MA, USA, 02139 |
| 電話號碼
| +1 617 586-3100 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.foghorntx.com |
| 員工數量
| 112 |
| Mr. Jeff Sacher |
Treasurer |
-- |
23/02/2026 |
| Dr. Alfonso Quintas-Cardama, M.D. |
Chief Medical Officer |
-- |
05/05/2025 |
| Mr. Carlos Costa |
Chief People Officer |
-- |
05/05/2025 |
| Dr. Steven F. Bellon, PhD |
Chief Scientific Officer |
-- |
05/05/2025 |
| Mr. Adrian Gottschalk |
President, Chief Executive Officer and Director |
美元 601.50K |
05/05/2025 |
| Ms. Anna Rivkin, PhD |
Chief Business Officer |
美元 143.33K |
05/05/2025 |
| Mr. Michael J. LaCascia |
Chief Legal Officer |
-- |
05/05/2025 |
| Mr. Ryan D. Maynard |
Chief Financial Officer and Principal Accounting Officer |
-- |
23/02/2026 |
|
|
| Mr. Ian F. Smith |
Independent Director |
05/05/2025 |
| Mr. Stuart M. Duty |
Independent Director |
01/05/2025 |
| Mr. Adrian Gottschalk |
President, Chief Executive Officer and Director |
05/05/2025 |
| Dr. Michael Mendelsohn, M.D. |
Independent Director |
05/05/2025 |
| Dr. Balkrishan Gill, PhD |
Independent Director |
05/05/2025 |
| Dr. Scott Biller, PhD |
Independent Director |
05/05/2025 |
| Dr. Neil Gallagher, M.D. |
Independent Director |
01/05/2025 |
| Dr. Thomas J. Lynch, Jr,M.D. |
Independent Director |
05/05/2025 |
| Dr. Douglas G. Cole, M.D. |
Chairman of the Board |
05/05/2025 |
| Ms. B. Lynne Parshall, Esq.,J.D. |
Independent Director |
05/05/2025 |
|
|
|
|
